A type of neurological disorder characterized by recurrent seizures—transient neurological abnormalities caused by abnormal activity in the brain—or temporary alteration in one or more brain functions.
As the most common serious neurological condition in the U.S., epilepsy affects roughly 3.4 million Americans. It's what drives biopharmaceutical researchers to fight back with innovative medicines like targeted treatments that could transform the lives of patients living with the disease.
Epilepsy is a complex condition, and it will take an equally complex approach to put an end to the disease. America's biopharmaceutical companies will not be satisfied until that goal is reached.